Document:

Amended and Restated Managing Director Contract

 Exhibit 10.3 
 Zwischen 
 Microtune GmbH & Co. KG, Marie-Curie-Straße 1 in 85055 Ingolstadt 
 (im folgenden Gesellschaft genannt) 
 und 
 Herrn Barry Koch 
 (im folgenden Geschäftsführer genannt)

 wird folgender 
 Geschäftsführervertrag 
 geschlossen: 
 § 1 Geschäftsführung und Vertretung 
  

	1.	Der Geschäftsführer ist berechtigt und verpflichtet, die Gesellschaft nach Maßgabe der Gesetze, des Gesellschaftsvertrages und dieses Vertrages zu vertreten und die
Geschäfte der Gesellschaft zu führen. Ist er alleine zum Geschäftsführer, dann vertritt er die Gesellschaft alleine. Weisungen der Gesellschafterversammlung sind zu befolgen, soweit Vereinbarungen in diesem Vertrag nicht
entgegenstehen. 

  

	2.	Der Geschäftsführer hat die ihm obliegenden Pflichten mit der Sorgfalt eines ordentlichen und gewissenhaften Kaufmannes wahrzunehmen. 

  

	3.	Der Geschäftsführer ist von den Bestimmungen des § 181 BGB befreit. 

  

	4.	Dem Geschäftsführer obliegt die verantwortliche Leitung und Überwachung des Unternehmens im ganzen auch für den Fall, daß mehrere Geschäftsführer
bestellt sind. 

 Between 
 Microtune
GmbH & Co. KG, Marie-Curie-Straße 1 in 85055 Ingolstadt 
 (hereafter referred to as the “Company”) 
 and 
 Mr. Barry F. Koch 
 (“Managing Director”) 
 is set up the following 
 Managing Director Contract 
 (as
amended and restated) 
 Mr. Barry F. Koch has been employed as Managing Director of Microtune GmbH & Co. KG, Ingolstadt, since
17 May 2000 on the basis of the original managing director agreement dated 28 August 2000 (“Original Agreement”). 
 The Original
Agreement is hereby amended and restated and fully replaced by this amended and restated Managing Director Contract effective as of 24 October 2007 (the “Managing Director Contract” or this “agreement”). 
 § 1 General Management and Representation 
  

	1.	The Managing Director has the right and the obligation to represent the Company according to the laws, Articles of Association as well as this agreement, and to manage the business
of the Company. In the case he is appointed as sole Managing Director, he represents the Company alone. Shareholders’ resolutions have to obeyed in so far as they pose no conflict with the terms of this agreement. 

  

	2.	The Managing Director is obliged to perform his duties with the thoroughness and care expected from a reasonable and conscientious Manager. 

  

	3.	The Managing Director is freed from the regulations of § 181 BGB. 

  

	4.	The complete responsibility for leading and control of the Company is incumbent upon 

 § 2 Bezüge des Gesellschafters 
  

	1.	Der Geschäftsführer erhält ein festes Monatsgehalt von EUR 11.777,—. Das Gehalt wird jeweils zum Monatsende ausbezahlt. Das Grundgehalt des Managing Directors
wird periodisch überpruft und ggf. angepasst. 

  

	2.	Im Krankheitsfall oder bei sonstiger unverschuldeter Verhinderung bleibt der Gehaltsanspruch für die Dauer von 12 Monaten bestehen. Im Einzelfall prüft die Gesellschaft
eine weitergehende Sicherung auf freiwilliger Basis. 

  

	3.	Stirbt der Gesellschafter, so wird den Hinterbliebenen (der Witwe oder, wenn nur eheliche Kinder vorhanden sind, den Kindern) das feste Gehalt (§ 2 Pkt. 1 bezogen auf das zum
Zeitpunkt des Ablebens geltende Monatsgehalt) anteilsmäßig für die Dauer von 12 Monaten weiterbezahlt. 

  

	4.	Dem Geschäftsführer wird ein Dienstwagen der oberen Mittelklasse seiner Wahl zur Verfügung gestellt. Die Privatnutzung des Fahrzeuges ist gestattet. Der
Geschäftsführer wird die Versteuerung des geldwerten Vorteils vornehmen. 

 § 3 Altersversorgung 
 Die betriebliche Altersversorgung bestimmt sich nach den entsprechenden betrieblichen Altersversorgungswerk. 
 § 4 Unfallversicherung 
 Die Gesellschaft gewährt dem
Geschäftsführer durch Abschluß einer Unfallversicherung gegen Unfälle jeder Art in Höhe folgender Versicherungssummen: 
  

	 	•	 	 4 Jahresgehälter im Todesfall 

  

	 	•	 	 4 Jahresgehälter im Invaliditätsfall bei Vollinvalidität, andernfalls anteilig 

 the Managing Director, even in the event that there are appointed several Managing Directors. 
 § 2 Compensation 
  

	1.	The Managing Director’s current base salary shall be paid at a rate of EUR 11,777 per month. The payment will take place monthly, effective month’s end. The Managing
Director’s base salary shall be subject to periodic review and adjustment without the necessity of amending this agreement. 

  

	2.	In case of sickness or other hindrance through no fault of the Managing Director, the salary noted above (or as in effect at the time) will continue to be paid for a 12-month
period. In particular cases, the Company has the option to voluntary extend payments. 

  

	3.	In case of death of the Managing Director, his surviving dependents (widow, or when only children are surviving, said children) will receive the base salary (§ 2 No. 1
with the actual amount at date of death) for a further period of 12 months. 

  

	4.	The Company will provide the Managing Director with a company car in the upper middle class of his own choice. Private use of the company car is allowed. The Managing Director is
liable for taxation based on the non-monetary income value of the company car. 

 § 3 Pension 
 The Pension of the Managing Director is as defined in the pension plan of the Company. 
 § 4 Accident Insurance 
 The Company will set up an insurance against accidents of all types for the Managing
Director with the following insured sums: 
  

	 	•	 	 4 years effective salary in case of death 

  

	 	•	 	 4 years effective salary in case of full disablement, in other cases proportional to the level of disablement 

 § 5 Urheberrechte 
 Der Geschäftsführer ist damit einverstanden, daß alle Rechte aus Erfindungen, Entwicklungen, Konzepten, Warenzeichen sowie sonstigen schutzfähigen Rechten, die er während der Dauer dieses Vertrages auf einem den
Geschäftszweig der Gesellschaft berührenden Gebiet macht, der Gesellschaft unabhängig von Ihrer Schutzfähigkeit zuzustehen und durch die in § 2 festgelegte Vergütung abgegolten werden. Er wirkt dabei mit, die
erforderlichen Schutzrechte im In- und Ausland für die Gesellschaft zu erwerben. Im übrigen gilt das Gesetz über Arbeitnehmererfindungen entsprechend. 
 § 6 Verschwiegenheitspflicht 
  

	1.	Der Geschäftsführer hat über vertrauliche Angaben und Geheimnisse der Gesellschaft, namentlich Betriebs oder Geschäftsgeheimnisse, die ihm durch seine
Tätigkeit für die Gesellschaft bekannt geworden sind, Stillschweigen zu bewahren. 

  

	2.	Geschäftliche Unterlagen jeder Art, die während seiner Tätigkeit in seinen Besitz gelangen, bleiben Eigentum der Gesellschaft. Er hat sie auf Verlangen, bei
Beendigung des Dienstverhältnisses auch ohne Aufforderung, auszuhändigen. Ein Zurückbehaltungsrecht ist ausge-schlossen. 

 § 7 Aufwendungsersatz 
  

	1.	Trägt der Geschäftsführer im Rahmen seiner ordnungsgemäßen Geschäftsführertätigkeit Kosten und Aufwendungen, so werden sie ihm von der
Gesellschaft erstattet, sofern der Geschäftsführer die Geschäftsführungs- und Betriebsbedingtheit belegt oder sie offenkundig ist. 

  

	2.	Die Gesellschaft ersetzt dem Geschäftsführer seine Reisespesen nach den jeweils steuerlich zulässigen Höchstwerten. Der Geschäftsführer muß seine
Auslagen belegen können, soweit üblicherweise Belege erteilt werden. Im übrigen reichen Eigenbelege aus. 

  

	3.	Der Geschäftsführer muß bei Flugreisen im Inland die einfache Klasse benutzen, bei sonstigen Flügen ist er in der Wahl der Klasse frei.

 § 5 Copyrights 
 The Managing
Director agrees that all rights of inventions, developments, concepts, trade marks and other protected rights, which he creates during the term of this agreement, related to the business of the Company, will belong to the Company without any
additional payments besides the compensation in § 2. He will help to obtain the necessary copyrights in Germany and in foreign countries. In addition the Gesetz über Arbeitnehmererfindungen (laws for employee inventions) are in effect.

 § 6 Obligation for discretion 
  

	1.	The Managing Director is obliged to keep confidential all sensitive information and secrets of the Company, especially business data, of which he gains knowledge as Managing
Director. 

  

	2.	All business documents he receives while acting as Managing Director remain the property of the Company. In case of termination he is obliged to return these documents. The right to
keep such documents is excluded. 

 § 7 Compensation of expenses 
  

	1.	If the Managing Director incurs costs related to the execution of his duties, the Company agrees to reimburse these charges, as long as the Managing Director can prove the necessity
of such expenses in cases where this is not generally obvious. 

  

	2.	The Company has to reimburse the Managing Director for all travel expenses according to the maximal amounts allowed by German tax regulations. The Managing Director has to document
his travel expenses, through receipts in cases where a receipt is usually provided. 

  

	3.	The Managing Director is obliged to use the Economy Class for domestic flights, while for other flights he may choose the class freely. 

 § 8 Dauer, Kündigung 
  

	1.	Die Tätigkeit als Geschäftsführer beginnt am 17. Mai 2000. 

  

	2.	Der Vertrag wird auf unbestimmte Zeit geschlossen. 

  

	3.	Der Vertrag kann von der Gesellschaft oder dem Geschäftsführer ordentlich mit einer Kündigungsfrist von 3 Monaten gekündigt werden. Die Möglichkeit zur
Kündigung des Vertrages aus wichtigem Grund bleibt unberührt. 

 § 9 Schlußbestimmungen 
  

	1.	Die Ungültigkeit einzelner Bestimmungen berührt nicht die Rechtswirksamkeit des Vertrages im Ganzen. Die unwirksame Bestimmung wird durch eine wirksame ersetzt, die dem
wirtschaftlich Gewolltem am nächsten kommt. 

  

	2.	Änderungen und Ergänzungen dieses Vertrages bedürfen der Schriftform. 

  

	3.	Im Verhältnis zum Geschäftsführer wird die Gesellschaft durch die Gesellschafterversammlung vertreten. 

 § 8 Termination 
  

	 1.
	 This Managing Director Contract is effective as of May 17th, 2000. 

  

	2.	There is no fixed date of termination. 

  

	3.	Either the Company or the Managing Director can terminate this agreement with a period of 3 months advance notice. The possibility to terminate this agreement based on an important
reason is not waived. 

 § 9 Others 
  

	1.	The invalidity of one or more sections of this agreement does not invalidate the agreement in whole. The invalid statement or section should be replaced by a valid statement or
section, which is the closest to the original intent. 

  

	2.	Any and all changes and supplements of this agreement must be in written form. 

  

	3.	In the relationship to the Managing Director the Company is represented by the shareholders. 

  

							
	Ingolstadt, den 24. Oktober 2007	 		 	Microtune GmbH & Co. KG
				
		 		 	By:	 	 Microtune Verwaltungs GmbH,
 its general
partner

				
		 		 	By:	 	 HMTF Bermuda (Acquisition) Ltd.,
 its indirect sole
stockholder

				
	 /s/ Barry F. Koch
	 		 	By:	 	 /s/ James A. Fontaine

	Managing Director	 		 	Name:	 	James A. Fontaine
		 		 	Title:	 	President of HMTF Bermuda (Acquisition) Ltd. and President and CEO of Microtune, Inc. (indirect sole stockholder of HMTF Bermuda (Acquisition) Ltd.)Offer Letter

 Exhibit 10.34 
 October 3, 2007 
 John G. Curd, M.D. 
 [Address]

  

	Re:	Employment Terms 

 Dear John, 
 This letter confirms that Threshold Pharmaceuticals, Inc. (the “Company”) has offered you the position of President and Chief Medical Officer, effective on
Monday, October 22, 2007 (or sooner) on the following terms: 
 You will report to the CEO of the
company and work at our facility located at 1300 Seaport Blvd., 5th Floor, Redwood City, CA 94063. Of course, the Company may change your position, duties
and work location from time to time as it deems necessary. 
 Your compensation will be $29,166.67 per month, or $350,000 per year, less payroll
deductions and all required withholdings. You will be paid semi-monthly and will be eligible for all standard Company benefits. The Company may modify compensation and benefits from time to time as it deems necessary. 
 Subject to the approval of the Company’s Board of Directors, you will be awarded a stock option grant to purchase 470,000 shares of the Company’s Common Stock
subject to a four year vesting schedule as follows: (a) the first 25% of this grant shall vest at your first anniversary of your starting date with the Company and (b) thereafter an additional 1/48th of the grant shall vest on each
subsequent monthly anniversary of your starting date. The exercise price of your stock option will be equal to the closing price of the Company’s Common Stock on date your option is approved by the Board of Directors, and the option will be
subject to the provisions of the Company’s 2004 Equity Incentive Plan and standard form option agreement. 
 You will be eligible for an annual
performance-based bonus of up to 30% of your base salary. This bonus will be awarded at the sole discretion of the Board of Directors. 
 You will also be
eligible to receive “double trigger” change of control benefits pursuant to a Change of Control Agreement that will generally provide that in the event that your employment with Threshold is terminated without cause or involuntarily
terminated within 18 months after a change of control, then you will be entitled to 12 months of base salary as of the date of termination or, if greater, as in effect in the year in which the change of control occurs, immediate acceleration and
vesting of all stock options granted prior to the change of control, the termination of our right to repurchase shares of restricted stock issued prior to the change of control, extension of the exercise period for stock options granted prior to the
change of control to two years following the date of termination and up to 12 months of health benefits. 

 Michael Brawer, M.D. 
 Page 2 of 2 
  

 As a Company employee, you will be expected to abide by Company rules and regulations, sign and comply with the
attached Proprietary Information and Inventions Agreement which prohibits unauthorized use or disclosure of Company proprietary information and, once it is available, acknowledge in writing that you have read the Company’s Employee Handbook.

 In your work for the Company, you will be expected not to use or disclose any confidential information, including trade secrets, of any former employer or
other person to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in
the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. During our discussions about your proposed job duties, you assured us that you would be able to perform those duties within the
guidelines just described. 
 You agree that you will not bring onto Company premises any unpublished documents or property belonging to any former employer
or other person to whom you have an obligation of confidentiality. 
 You may terminate your employment with the Company at any time and for any reason
whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time and for any reason whatsoever, with or without cause or advance notice. As required by law, this offer is subject to satisfactory proof of
your right to work in the United States. A “Lists of Acceptable Documents” for employment eligibility verification is attached for your information. 
 This letter, together with your Proprietary Information and Inventions Agreement, forms the complete and exclusive statement of your employment agreement with the Company. The employment terms in this letter supersede any other agreements
or promises made to you by anyone, whether oral or written. This letter agreement cannot be changed except in writing signed by you and a duly authorized officer of the Company. 
 Please indicate your acceptance of our offer by signing below and returning the original copy of this letter of employment from Threshold Pharmaceuticals under the terms described above. This offer will remain until
end of day Friday, October 12, 2007. Should you have any questions, please contact me at (650) 474-8205. 
 John, on behalf of the entire Threshold
team, we look forward to your joining us in helping to develop the types of pharmaceutical drugs that will make a significant difference in patients’ lives. 
 Sincerely, 
  

							
	 /s/ Harold E. Selick
	 		 		 	
	Harold E. Selick, Ph.D.	 		 	
	Chief Executive Officer	 		 		 	
				
	Accepted:	 		 		 	
				
	 /s/ John G. Curd
	 		 	 10/19/2007
	 	
	John G. Curd, M.D.	 		 	Date	 	

 Enclosures:    Change of Control Severance Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}]]